A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
NCT ID: NCT06462404
Last Updated: 2025-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
22 participants
INTERVENTIONAL
2024-06-20
2025-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
NCT06470828
A Study of TAK-994 in Adults With Narcolepsy
NCT04820842
A Study of TAK-861 in People With Narcolepsy Type 1
NCT06505031
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
NCT00424931
A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
NCT04096560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1, ABECD: Placebo + E2086 Dose 1 + Active Comparator + E2086 Dose 2 + E2086 Dose 3
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 2, BCADE: E2086 Dose 1 + E2086 Dose 2 + Placebo + E2086 Dose 3 + Active Comparator
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 3, CDBEA: E2086 Dose 2 + E2086 Dose 3 + E2086 Dose 1 + Active Comparator + Placebo
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 4, DECAB: E2086 Dose 3 + Active Comparator + E2086 Dose 2 + Placebo + E2086 Dose 1
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 5, EADBC: Active Comparator + Placebo + E2086 Dose 3 + E2086 Dose 1 + E2086 Dose 2
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 6, DCEBA: E2086 Dose 3 + E2086 Dose 2 + Active Comparator + E2086 Dose 1 + Placebo
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 7, EDACB: Active Comparator + E2086 Dose 3 + Placebo + E2086 Dose 2 + E2086 Dose 1
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 8, AEBDC: Placebo + Active Comparator + E2086 Dose 1 + E2086 Dose 3 + E2086 Dose 2
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 9, BACED: E2086 Dose 1 + Placebo + E2086 Dose 2 + Active Comparator + E2086 Dose 3
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Sequence 10, CBDAE: E2086 Dose 2 + E2086 Dose 1 + E2086 Dose 3 + Placebo + Active Comparator
Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E2086
E2086 oral tablets.
E2086 Placebo
E2086 matching placebo tablet.
Active Comparator
Active comparator oral tablets.
Active Comparator Placebo
Active comparator matching placebo tablet.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of NT1 defined by the following criteria:
* History of daily periods of the irrepressible need to sleep, or daytime lapses into sleep, occurring for at least 3 months
* History of cataplexy (which must be confirmed during the Screening Period by Sleep/Cataplexy Diary)
* At least one of the following:
* On Screening multiple sleep latency test (MSLT): MSL of less than or equal to (\<=) 8 minutes and 2 or more sleep onset rapid eye movement periods (SOREMPs) on an MSLT performed according to standard techniques
* On Screening nocturnal polysomnography (PSG): One or more SOREMPs within 15 minutes of sleep onset
3. Epworth Sleepiness Scale score \>=10
4. Reports regular bedtime, defined as the time that the participant attempts to sleep, between 22:00 and midnight (based on data from the Screening Sleep/Cataplexy Diary)
5. Reports regular waketime, defined at the time the participant gets out of bed for the day, between 05:00 and 10:00 (based on data from the Screening Sleep/Cataplexy Diary)
6. Reports being in bed between 7 and 9 hours per night (based on data from the Screening Sleep/Cataplexy Diary)
7. Body mass index (BMI) \>=18 to less than (\<) 40 kilograms per meter square (kg/m\^2), at Screening
Exclusion Criteria
2. Females of childbearing potential who:
* Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:
* total abstinence (if it is their preferred and usual lifestyle)
* a nonhormonal intrauterine device (example, "coil") or a progesterone-only intrauterine hormone-releasing system
* a nonsteroidal oral contraceptive (participant must have been on a stable dose of the same nonsteroidal oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
* depot medroxyprogesterone acetate or depot norethisterone enantate.
* have a vasectomized partner with confirmed azoospermia.
* Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 30 days after study drug administration.
* Participants on an oral contraceptive must use an additional barrier method throughout the study and for 30 days after study drug administration.
NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that are, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
4. History of myocardial infarction, ischemic heart disease, or cardiac failure at Screening
5. History of clinically significant arrhythmia or uncontrolled arrhythmia
6. Known to have or probable positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 14 days of any study visit.
7. Exposure within the last 10 days to an individual with confirmed or probable coronavirus disease-2019 (COVID-19) or symptoms within the last 10 days that are on the most recent Centers for Disease Control and Prevention (CDC) list of COVID symptoms
8. Hypersensitivity to excipients of the study drug (E2086), or to active comparator or any of its excipients
9. Any suicidal ideation with intent with or without a plan at Screening or within 6 months of Screening (that is, answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the CSSRS)
10. Any lifetime suicidal behavior (per the Suicidal Behavior section of the C-SSRS)
11. Any history of psychiatric disease (including but not limited to depression or other mood disorders, bipolar disorder, psychotic disorders, including schizophrenia, panic attacks, anxiety disorders), within 10 years of Screening
12. Any current psychiatric symptoms as indicated by a standard screening tool (Diagnostic and Statistical Manual of Mental Disorders \[DSM-5\] Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult)
13. Participants with one or more 1st degree (blood) relatives who have lifetime diagnosis of bipolar type I disorder or a psychotic disorder
14. Psychotic disorder(s) or unstable recurrent affective disorder(s) evident by use of antipsychotics within 2 years before Screening
15. Evidence of clinically significant disease (examples, allergies; cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
16. Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, ECG finding, or laboratory test results that require medical treatment at Screening or Baseline
17. Any history of or concomitant medical condition that in the opinion of the investigator(s) would compromise the participant's ability to safely complete the study.
18. History of drug or alcohol dependency or abuse within 2 years before Screening
19. Use of illegal recreational drugs at Screening and throughout the study
20. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing
21. Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5\* the half-life, (whichever is longer) preceding informed consent.
22. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing (examples, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system)
23. History of formally diagnosed moderate to severe obstructive sleep apnea, current use of continuous positive airway pressure, or symptomatic restless legs syndrome
24. Apnea-hypopnea index \>=15 on Screening PSG
25. Periodic limb movement arousal index (PLMAI)\>=15 on Screening PSG
26. Use of anti-cataplectic medications within 5\* the half-life before Screening
27. Use of psychostimulant medications, prescription and over-the-counter (OTC), within 5\*the half-life before Screening
\- Examples of prohibited medications include OTC stimulants (example, pseudoephedrine), methylphenidate, amphetamines, modafinil, armodafinil, sodium oxybate, and pemoline
28. Use of sleep promoting medications, prescription and OTC, within 28 days or 5\*the half-life before Screening - Examples of prohibited medication include OTC sleep aids, trazodone, hypnotics, benzodiazepines, barbiturates, cannabinoids, and opioids.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SDS Clinical Trials
Santa Ana, California, United States
PharmaDev Clinical Research
Miami, Florida, United States
Sleep Practioners, LLC
Macon, Georgia, United States
Clinical Research Institute
Stockbridge, Georgia, United States
Sound Asleep Research, Inc.
Lansing, Michigan, United States
Research Carolina Elite
Denver, North Carolina, United States
Medical Care Inc.
Goldsboro, North Carolina, United States
Advances Repiratory and Sleep Medicine
Greensboro, North Carolina, United States
Intrepid Research, LLC
Cincinnati, Ohio, United States
Bogan Sleep Consultants, LLC
Columbia, South Carolina, United States
Sleep Therapy and Research Center
San Antonio, Texas, United States
Comprehensive Sleep Medicine Associates
Sugar Land, Texas, United States
AMDX Inc.
Markham, Ontario, Canada
Jodha Tishon Inc
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2086-A001-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.